

Kaushik Thanki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7575275/publications.pdf>

Version: 2024-02-01

52
papers

2,477
citations

185998

28
h-index

197535

49
g-index

52
all docs

52
docs citations

52
times ranked

3416
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral delivery of anticancer drugs: Challenges and opportunities. <i>Journal of Controlled Release</i> , 2013, 170, 15-40.	4.8	403
2	Co-encapsulation of Tamoxifen and Quercetin in Polymeric Nanoparticles: Implications on Oral Bioavailability, Antitumor Efficacy, and Drug-Induced Toxicity. <i>Molecular Pharmaceutics</i> , 2013, 10, 3459-3474.	2.3	210
3	Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. <i>Biomaterials</i> , 2012, 33, 6758-6768.	5.7	159
4	Improved Stability and Antidiabetic Potential of Insulin Containing Folic Acid Functionalized Polymer Stabilized Multilayered Liposomes Following Oral Administration. <i>Biomacromolecules</i> , 2014, 15, 350-360.	2.6	141
5	Gelatin Coated Hybrid Lipid Nanoparticles for Oral Delivery of Amphotericin B. <i>Molecular Pharmaceutics</i> , 2012, 9, 2542-2553.	2.3	113
6	Novel self-emulsifying formulation of quercetin for improved in vivo antioxidant potential: Implications for drug-induced cardiotoxicity and nephrotoxicity. <i>Free Radical Biology and Medicine</i> , 2013, 65, 117-130.	1.3	94
7	Enhanced Antitumor Efficacy and Reduced Toxicity of Docetaxel Loaded Estradiol Functionalized Stealth Polymeric Nanoparticles. <i>Molecular Pharmaceutics</i> , 2015, 12, 3871-3884.	2.3	72
8	Positively charged self-nanoemulsifying oily formulations of olmesartan medoxomil: Systematic development, in vitro, ex vivo and in vivo evaluation. <i>International Journal of Pharmaceutics</i> , 2015, 493, 466-482.	2.6	68
9	Bicontinuous Cubic Liquid Crystalline Nanoparticles for Oral Delivery of Doxorubicin: Implications on Bioavailability, Therapeutic Efficacy, and Cardiotoxicity. <i>Pharmaceutical Research</i> , 2014, 31, 1219-1238.	1.7	66
10	Solidified Self-Nanoemulsifying Formulation for Oral Delivery of Combinatorial Therapeutic Regimen: Part I. Formulation Development, Statistical Optimization, and In Vitro Characterization. <i>Pharmaceutical Research</i> , 2014, 31, 923-945.	1.7	65
11	Engineering of small interfering RNA-loaded lipidoid-poly(DL-lactic-co-glycolic acid) hybrid nanoparticles for highly efficient and safe gene silencing: A quality by design-based approach. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 120, 22-33.	2.0	53
12	Novel self-nanoemulsifying formulation of quercetin: Implications of pro-oxidant activity on the anticancer efficacy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, e959-e969.	1.7	48
13	Lipidoid-polymer hybrid nanoparticles loaded with TNF siRNA suppress inflammation after intra-articular administration in a murine experimental arthritis model. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 142, 38-48.	2.0	46
14	Oral Bioavailability and Pharmacodynamic Activity of Hesperetin Nanocrystals Generated Using a Novel Bottom-up Technology. <i>Molecular Pharmaceutics</i> , 2015, 12, 1158-1170.	2.3	43
15	Î±-Tocopherol as functional excipient for resveratrol and coenzyme Q10-loaded SNEDDS for improved bioavailability and prophylaxis of breast cancer. <i>Journal of Drug Targeting</i> , 2017, 25, 554-565.	2.1	43
16	Enhanced antitumor efficacy and counterfeited cardiotoxicity of combinatorial oral therapy using Doxorubicin- and Coenzyme Q10-liquid crystalline nanoparticles in comparison with intravenous Adriamycin. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 1231-1241.	1.7	42
17	Inhalable siRNA-loaded nano-embedded microparticles engineered using microfluidics and spray drying. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 120, 9-21.	2.0	40
18	Systematic development of novel cationic self-nanoemulsifying drug delivery systems of candesartan cilexetil with enhanced biopharmaceutical performance. <i>RSC Advances</i> , 2015, 5, 71500-71513.	1.7	39

#	ARTICLE	IF	CITATIONS
19	Triple antioxidant SNEDDS formulation with enhanced oral bioavailability: Implication of chemoprevention of breast cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 1431-1443.	1.7	39
20	Identification of Factors of Importance for Spray Drying of Small Interfering RNA-Loaded Lipidoid-Polymer Hybrid Nanoparticles for Inhalation. <i>Pharmaceutical Research</i> , 2019, 36, 142.	1.7	39
21	Combinatorial bio-conjugation of gemcitabine and curcumin enables dual drug delivery with synergistic anticancer efficacy and reduced toxicity. <i>RSC Advances</i> , 2014, 4, 29193-29201.	1.7	38
22	Enhanced Transfection Efficiency and Reduced Cytotoxicity of Novel Lipid-Polymer Hybrid Nanoplexes. <i>Molecular Pharmaceutics</i> , 2013, 10, 2416-2425.	2.3	35
23	Dissolution Improvement of Simvastatin by Surface Solid Dispersion Technology. <i>Dissolution Technologies</i> , 2010, 17, 27-34.	0.2	33
24	Mechanistic profiling of the release kinetics of siRNA from lipidoid-polymer hybrid nanoparticles in vitro and in vivo after pulmonary administration. <i>Journal of Controlled Release</i> , 2019, 310, 82-93.	4.8	33
25	Macromolecular Bipill of Gemcitabine and Methotrexate Facilitates Tumor-Specific Dual Drug Therapy with Higher Benefit-to-Risk Ratio. <i>Bioconjugate Chemistry</i> , 2014, 25, 501-509.	1.8	31
26	Phytantriol Based "Stealth" Lyotropic Liquid Crystalline Nanoparticles for Improved Antitumor Efficacy and Reduced Toxicity of Docetaxel. <i>Pharmaceutical Research</i> , 2015, 32, 3282-3292.	1.7	31
27	Engineering of budesonide-loaded lipid-polymer hybrid nanoparticles using a quality-by-design approach. <i>International Journal of Pharmaceutics</i> , 2018, 548, 740-746.	2.6	31
28	Long chain fatty acid conjugation remarkably decreases the aggregation induced toxicity of Amphotericin B. <i>International Journal of Pharmaceutics</i> , 2018, 544, 1-13.	2.6	30
29	Solidified Self-Nanoemulsifying Formulation for Oral Delivery of Combinatorial Therapeutic Regimen: Part II In vivo Pharmacokinetics, Antitumor Efficacy and Hepatotoxicity. <i>Pharmaceutical Research</i> , 2014, 31, 946-958.	1.7	29
30	Immunogenicity Testing of Lipidoids In Vitro and In Silico: Modulating Lipidoid-Mediated TLR4 Activation by Nanoparticle Design. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 11, 159-169.	2.3	27
31	Lyotropic Liquid Crystalline Nanoparticles of CoQ10: Implication of Lipase Digestibility on Oral Bioavailability, <i>in Vivo</i> antioxidant activity, and <i>in Vitro</i> "in Vivo" Relationships. <i>Molecular Pharmaceutics</i> , 2014, 11, 1435-1449.	2.3	26
32	Cyclosporine A loaded self-nanoemulsifying drug delivery system (SNEDDS): implication of a functional excipient based co-encapsulation strategy on oral bioavailability and nephrotoxicity. <i>RSC Advances</i> , 2015, 5, 49633-49642.	1.7	26
33	Improved Oral Bioavailability and Gastrointestinal Stability of Amphotericin B through Fatty Acid Conjugation Approach. <i>Molecular Pharmaceutics</i> , 2019, 16, 4519-4529.	2.3	22
34	Mechanistic Evaluation of the Effect of Sintering on Compritol® 888 ATO Matrices. <i>AAPS PharmSciTech</i> , 2009, 10, 355-360.	1.5	21
35	Formulating Inhalable Dry Powders Using Two-Fluid and Three-Fluid Nozzle Spray Drying. <i>Pharmaceutical Research</i> , 2018, 35, 247.	1.7	21
36	Identification of p38 MAP kinase inhibitors by pharmacophore based virtual screening. <i>Journal of Molecular Graphics and Modelling</i> , 2014, 49, 18-24.	1.3	20

#	ARTICLE	IF	CITATIONS
37	Development and in vitro evaluation of floating rosiglitazone maleate microspheres. Drug Development and Industrial Pharmacy, 2009, 35, 834-842.	0.9	19
38	Hyaluronic acid-PEI-cyclodextrin polyplexes: implications for in vitro and in vivo transfection efficiency and toxicity. RSC Advances, 2015, 5, 41144-41154.	1.7	19
39	Effect of co-administration of CoQ10-loaded nanoparticles on the efficacy and cardiotoxicity of doxorubicin-loaded nanoparticles. RSC Advances, 2013, 3, 14671.	1.7	18
40	Formulation of RNA interference-based drugs for pulmonary delivery: challenges and opportunities. Therapeutic Delivery, 2018, 9, 731-749.	1.2	18
41	Preparation, Characterization, and In Vitro Evaluation of Lipidoid-Polymer Hybrid Nanoparticles for siRNA Delivery to the Cytosol. Methods in Molecular Biology, 2019, 1943, 141-152.	0.4	18
42	Design and evaluation of microemulsion-based efinaconazole formulations for targeted treatment of onychomycosis through transungual route: Ex vivo and nail clipping studies. Colloids and Surfaces B: Biointerfaces, 2021, 201, 111652.	2.5	18
43	Mixed micellar system stabilized with saponins for oral delivery of vitamin K. Colloids and Surfaces B: Biointerfaces, 2018, 170, 521-528.	2.5	16
44	Design of Inhalable Solid Dosage Forms of Budesonide and Theophylline for Pulmonary Combination Therapy. AAPS PharmSciTech, 2019, 20, 137.	1.5	16
45	Effect of processing and sintering on controlled release wax matrix tablets of ketorolac tromethamine. Indian Journal of Pharmaceutical Sciences, 2009, 71, 538.	1.0	12
46	Application of a Quality-By-Design Approach to Optimise Lipid-Polymer Hybrid Nanoparticles Loaded with a Splice-Correction Antisense Oligonucleotide: Maximising Loading and Intracellular Delivery. Pharmaceutical Research, 2019, 36, 37.	1.7	11
47	Optimizing the Intracellular Delivery of Therapeutic Anti-inflammatory TNF- α siRNA to Activated Macrophages Using Lipidoid-Polymer Hybrid Nanoparticles. Frontiers in Bioengineering and Biotechnology, 2020, 8, 601155.	2.0	11
48	Enabling Oral Amphotericin B Delivery by Merging the Benefits of Prodrug Approach and Nanocarrier-Mediated Drug Delivery. ACS Biomaterials Science and Engineering, 2023, 9, 2879-2890.	2.6	9
49	Estradiol functionalized multi-walled carbon nanotubes as renovated strategy for efficient gene delivery. RSC Advances, 2016, 6, 10792-10801.	1.7	7
50	Recent Advances in Tumor Targeting Approaches. Advances in Delivery Science and Technology, 2015, , 41-112.	0.4	6
51	Mixed Micellar Nanocarriers for Controlled and Targeted Delivery of Paclitaxel. Journal of Nanopharmaceutics and Drug Delivery, 2014, 2, 69-79.	0.3	2
52	Immune Reactions in the Delivery of RNA Interference-Based Therapeutics: Mechanisms and Opportunities. , 2019, , 441-472.		0